The global artificial
insemination market is expected to reach USD 2.63 billion by 2025,
according to a new report by Grand View Research, Inc. Over the past few years,
infertility has become a major public health concern across the globe.
Artificial insemination is usually the preferred first-line treatment for
infertility. According to WHO, around 10% of women in the world are struggling
to get pregnant. Lifestyle changes, delay in pregnancy, and hormonal issues are
some of the reasons contributing to the rise in infertility around the world.
The exact estimation of infertility statistics is
challenging, however, WHO monitors its prevalence across the world. At present,
46% of the global population lives in countries having low levels of fertility.
According to United Nations, the global rate of fertility is expected to
decline to 2.4 by 2030 and 2.2 by 2050. In developing or underdeveloped
nations, medical consultation regarding infertility and childlessness was not
easily accessible. Hence, there was lack of awareness about available assisted
reproductive techniques including artificial or donor insemination and IVF.
Browse full research report on Artificial Insemination Market: https://www.grandviewresearch.com/industry-analysis/artificial-insemination-market
Further
Key Findings From the Report Suggest:
- Artificial insemination is a first-line infertility treatment as it
is minimally invasive and less expensive as compared to IVF
- It is preferred mostly by single women who wish to conceive and
same-sex partners with the help of fresh or frozen donor sperm samples. In
some countries, lesbian couples are provided insurance coverage for these
procedures
- Intrauterine Insemination (IUI) held majority of the market share
in 2017 and is likely to be the fastest-growing segment over the forecast
period, as it is the most common and noninvasive procedure.
- Fertility clinics held majority of the market share in 2017 as the
number of medical facilities offering infertility treatments has been
increasing over the past decade
- Fertility clinics provide medical consultation regarding the
detection of ovulation to perform the procedure for insemination. Sperm
washing is also performed in the clinics to achieve optimum results
- Artificial insemination with partner’s or (AIH) sample held the
majority of the source type segment share
- Europe held majority of the market share in 2017 due to the
presence of the largest number of patients and easily accessible treatment
options
- On the other hand, Asia Pacific is expected to be the
fastest-growing regional market due to increase in awareness regarding
artificial or donor insemination in the region
- Some of the key players in this market include Irvine Scientific;
Rinovum Women’s Health, LLC; TenderNeeds Fertility; Conceivex, Inc.;
Hi-Tech Solutions; among others.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/healthcare
Grand
View Research has segmented the Artificial Insemination market based on type,
end use,
source type and region:
Type
Outlook (Revenue, USD Million; 2014 - 2025)
- Intrauterine
Insemination
- Intracervical
Insemination
- Intravaginal
Insemination
- Intratubal
Insemination
End-use
Outlook (Revenue, USD Million; 2014 - 2025)
- Fertility
Clinics and Others
- Home
Source
Type Outlook (Revenue, USD Million; 2014 - 2025)
- AIH - Husband
- AID - Donor
Regional
Outlook (Revenue, USD Million; 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- Middle East
& Africa
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment